Quetiapine Fumarate Bipolar Maintenance Monotherapy (SPaRCLe)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00314184
First received: April 11, 2006
Last updated: December 19, 2008
Last verified: December 2008
  Purpose

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of quetiapine and lithium (comparator in the study) for up to 104 weeks of maintenance treatment in adult patients with Bipolar I Disorder.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Condition Intervention Phase
Bipolar Disorder
Drug: quetiapine fumarate
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Time from randomization to recurrence of a mood event

Secondary Outcome Measures:
  • Time from randomization to recurrence of a manic event
  • Time from randomization to recurrence of a depressed event

Enrollment: 1255
Study Start Date: March 2005
Study Completion Date: July 2007
Intervention Details:
    Drug: quetiapine fumarate
    Other Name: Seroquel
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • 18 years or older
  • A diagnosis of Bipolar I Disorder
  • Have a current manic, depressed or mixed episode
  • Have had a manic, depressed or mixed episode during the last 26 weeks that was treated with quetiapine
  • Female patients of childbearing potential must be using a reliable method of contraception

Exclusion Criteria:

  • Pregnancy
  • Substance or alcohol dependence at enrollment
  • Unstable thyroid function
  • Unstable Diabetes
  • Unstable or inadequately treated medical illness e.g., angina pectoris and hypertension
  • Use of an experimental drug within 30 days of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00314184

  Hide Study Locations
Locations
United States, California
Research Site
Cerritos, California, United States
Research Site
San Diego, California, United States
Research Site
Santa Ana, California, United States
United States, District of Columbia
Research Site
Washington, District of Columbia, United States
United States, Florida
Research Site
Gainesville, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
North Miami, Florida, United States
Research Site
Orlando, Florida, United States
United States, Georgia
Research Site
Atlanta, Georgia, United States
United States, Idaho
Research Site
Eagle, Idaho, United States
United States, Illinois
Research Site
Hoffman Estates, Illinois, United States
United States, Indiana
Research Site
Terre Haute, Indiana, United States
United States, Louisiana
Research Site
Shreveport, Louisiana, United States
United States, Mississippi
Research Site
Flowood, Mississippi, United States
United States, Missouri
Research Site
St. Charles, Missouri, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
United States, New Jersey
Research Site
Clementon, New Jersey, United States
United States, New York
Research Site
Rochester, New York, United States
United States, North Carolina
Research Site
Raleigh, North Carolina, United States
United States, North Dakota
Research Site
Fargo, North Dakota, United States
United States, Oregon
Research Site
Portland, Oregon, United States
Research Site
Salem, Oregon, United States
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States
United States, Tennessee
Research Site
Memphis, Tennessee, United States
United States, Texas
Research Site
Austin, Texas, United States
Research Site
Lake Jackson, Texas, United States
United States, Virginia
Research Site
Richmond, Virginia, United States
United States, Washington
Research Site
Bellevue, Washington, United States
Research Site
Kirkland, Washington, United States
Research Site
Seattle, Washington, United States
Argentina
Research Site
Capital Federal, Argentina
Research Site
Cordoba, Argentina
Research Site
La Plata, Argentina
Research Site
Lanus, Argentina
Research Site
Mendoza, Argentina
Research Site
Rosario, Argentina
Bulgaria
Research Site
Bourgas, Bulgaria
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Colombia
Research Site
Antioquia, Colombia
Research Site
Barranquilla, Colombia
Research Site
Bogota, Colombia
Research Site
Pereira, Colombia
India
Research Site
Ahmedabad, India
Research Site
Chennai, India
Research Site
Jaipur, India
Research Site
Kanpur, India
Research Site
Lucknow, India
Research Site
Mangalore, India
Research Site
Manipal, India
Research Site
Mumbai, India
Research Site
New Delhi, India
Research Site
Visakhapatnam, India
Lithuania
Research Site
Kaunas, Lithuania
Research Site
Klaipeda, Lithuania
Research Site
Vilnius, Lithuania
Malaysia
Research Site
Kuala Lumpur, Malaysia
Research Site
Sarawak, Malaysia
Mexico
Research Site
Leon, Mexico
Research Site
Mexico, Mexico
Research Site
San Luis Potosi, Mexico
Peru
Research Site
Lima, Peru
Philippines
Research Site
Cebu City, Philippines
Research Site
Davao City, Philippines
Research Site
Mandaluyong City, Philippines
Research Site
Manila, Philippines
Research Site
Quezon City, Philippines
Romania
Research Site
Arad, Romania
Research Site
Brasov, Romania
Research Site
Bucuresti, Romania
Research Site
Cluj-Napoca, Romania
Research Site
Com Jebel, Romania
Research Site
Craiova, Romania
Research Site
Iasi, Romania
Research Site
Oradea, Romania
Research Site
Pitesti, Romania
Research Site
Sibiu, Romania
Research Site
Targoviste, Romania
Research Site
Targu Mures, Romania
Russian Federation
Research Site
Kazan, Russian Federation
Research Site
Moscow, Russian Federation
Research Site
St. Petersburg, Russian Federation
Taiwan
Research Site
Kaohsiung Hsien, Taiwan
Research Site
Taipei, Taiwan
Research Site
Taoyuan City, Taiwan
Research Site
Taoyuan Hsien, Taiwan
Thailand
Research Site
Bangkok, Thailand
Ukraine
Research Site
Dnepropetrovsk, Ukraine
Research Site
Kharkiv, Ukraine
Research Site
Kiev, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Lviv, Ukraine
Research Site
Odessa, Ukraine
Research Site
Simferopol, Ukraine
Research Site
Vinnitsa, Ukraine
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: AstraZeneca CNS Medical Science Director, MD AstraZeneca
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00314184     History of Changes
Other Study ID Numbers: D1447C00144, EUDRACT 2004-000915-25
Study First Received: April 11, 2006
Last Updated: December 19, 2008
Health Authority: Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Bulgaria: Bulgarian Drug Agency
Chile: Instituto de Salud Pública de Chile
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
India: Ministry of Health
Lithuania: State Medicine Control Agency - Ministry of Health
Malaysia: Ministry of Health
Mexico: Federal Commission for Protection Against Health Risks
Peru: General Directorate of Pharmaceuticals, Devices, and Drugs
Philippines: Bureau of Food and Drugs
Romania: State Institute for Drug Control
Russia: Pharmacological Committee, Ministry of Health
Taiwan: Department of Health
Ukraine: State Pharmacological Center - Ministry of Health

Keywords provided by AstraZeneca:
Bipolar I disorder.

Additional relevant MeSH terms:
Disease
Bipolar Disorder
Pathologic Processes
Affective Disorders, Psychotic
Mood Disorders
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on September 18, 2014